Skip to content

A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia

Post Authorization Safety Study Assessing the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06714448
Acronym
DEPAKINE PASS
Enrollment
455
Registered
2024-12-03
Start date
2025-04-29
Completion date
2025-09-22
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy, Seizures

Brief summary

A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia. The end of study is defined as the end of the data collection period. No intervention will be administered, and no study related visits are required.

Interventions

DRUGSodium valporate

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Healthcare professionals working only in Saudi Arabia AND * Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR * Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR * Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion

Exclusion criteria

* Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies) * Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome * Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® \[sodium valproate\]) * Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of healthcare professionals who received and read the educational materials7 months
Healthcare professionals' knowledge score7 monthsKnowledge score is calculated as the proportion of correct responses among all questions related to knowledge
Healthcare professionals' behavior score7 monthsBehavior score is calculated as the proportion of correct responses among all questions related to behavior

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 29, 2026